TearLab Corporation

SAN DIEGO, Jan. 11, 2010 -- OccuLogix, Inc., dba TearLab Corporation ("TearLab") (Nasdaq:TEAR) (TSX:TLB) today announced the sale of 1,886,291 shares of its common stock for an aggregate of approximately $1,700,000. This is the maximum currently allowable by the rules of the NASDAQ Capital Market without stockholder approval.

SAN DIEGO, Dec. 8, 2009 -- OccuLogix, Inc. dba TearLab Corporation (Nasdaq:TEAR) (TSX:TLB), announced today that Health Canada has issued a Medical Device License for the TearLab Osmolarity System. TearLab is intended to measure the osmolarity of human tears to aid in the diagnosis of patients with signs or symptoms of Dry Eye Disease (DED), in conjunction with other methods of clinical evaluation. The Health Canada license allows the company to immediately begin marketing the system in Canada.

SAN DIEGO, Nov. 12, 2009 -- OccuLogix, Inc., dba TearLab Corporation (TearLab) (Nasdaq:TEAR) (TSX:TLB) today reported its consolidated financial results for the quarter ended September 30, 2009. All dollar amounts are expressed in U.S. currency, and results are reported in accordance with United States generally accepted accounting principles.

SAN DIEGO, CALIFORNIA--(November 4, 2009) - OccuLogix, Inc. dba TearLab Corporation (NASDAQ:TEAR)(TSX:TLB) expects to announce its third quarter 2009 financial results after the market closes on Thursday, November 12, 2009.

SAN DIEGO, Oct. 26, 2009 -- OccuLogix, Inc. dba TearLab Corporation (Nasdaq:TEAR) (TSX:TLB) announced that Gary Foulks, MD, FACS, presented the poster, "Osmolarity as a Biomarker for Disease Severity in Mild to Moderate Dry Eye Disease," from the TearLab Osmolarity Core Validation Study today at the 2009 American Academy of Ophthalmology (AAO) and Pan American Ophthalmology (PAAO) joint meeting in San Francisco, California.

SAN DIEGO, Aug. 12, 2009 -- OccuLogix, Inc., dba TearLab Corporation (Tearlab) (Nasdaq:TEAR) (TSX:TLB) today reported its consolidated financial results for the quarter ended June 30, 2009. All dollar amounts are expressed in U.S. currency, and results are reported in accordance with United States generally accepted accounting principles.

SAN DIEGO, July 16, 2009 -- OccuLogix, Inc. dba TearLab Corporation (Nasdsaq:TEAR)(TSX:TLB) (the "Company) today announced that it has entered into and closed an agreement with certain investors whereby the investors agreed to provide financing (the "Financing") to the Company through the purchase of convertible secured notes, in the aggregate amount of $1.55 million. The convertible secured notes (the "Notes") evidencing the Financing, mature on the second anniversary of their issuance ("the Maturity Date"), bear interest at a rate of 12% per annum and are convertible into shares of the Company's common stock upon the request of holders of 51% or more of the outstanding principal amount of the Notes at any time after August 31, 2009 and prior to the Maturity Date. The conversion price of the Notes (the "Discount Price") will be 80% of the volume weighted average price on the NASDAQ stock market for the ten trading days prior to August 31, 2009, provided that the Discount Price will not exceed $2.40 per share and will not be less than $0.25 per share. Any such conversion is limited to prevent the number of shares issued upon conversion of the Notes from exceeding 19.9% of the outstanding common stock of the Company, measured prior to the date of the Financing.

San Diego, CA, June 29, 2009 OccuLogix, Inc. dba TearLab Corporation (Nasdaq:TEAR; TSX:TLB) today announced that its Chief Executive Officer, Eric Donsky, is leaving the company to pursue other opportunities effective Immediately. The Company’s Board of Directors has appointed its Chairman, Elias Vamvakas, to serve as Interim Chief Executive Officer until a permanent replacement for Mr. Donsky can be found.

SAN DIEGO, June 12, 2009 -- OccuLogix, Inc. dba TearLab Corporation (Nasdaq:TEAR) (TSX:TLB) today announced that its TearLab(tm) Osmolarity System has received a Silver 2009 Medical Design Excellence Award (MDEA).

SAN DIEGO, May 19, 2009 -- OccuLogix, Inc. dba TearLab Corporation (Nasdaq:TEAR) (TSX:TLB) an ophthalmic, in-vitro diagnostics company, today announced FDA 510(k) clearance of its award winning TearLab Osmolarity System. The TearLab Osmolarity System is intended to measure the osmolarity of human tears to aid in the diagnosis of patients with signs or symptoms of Dry Eye Disease (DED), in conjunction with other methods of clinical evaluation. The 510(k) clearance allows the Company to immediately begin market activities in the U.S. to clinical facilities categorized as high or moderate complex under the Clinical Laboratory Improvement Act of 1988 (CLIA '88).

SAN DIEGO, May 14, 2009 -- OccuLogix, Inc., dba TearLab Corporation (TearLab) (Nasdaq:TEAR) (TSX:TLB) today reported its consolidated financial results for the quarter ended March 31, 2009. All dollar amounts are expressed in U.S. currency, and results are reported in accordance with United States generally accepted accounting principles.

SAN DIEGO, April 9, 2009 -- OccuLogix, Inc. dba TearLab Corporation (Nasdaq:TEAR) (TSX:TLB) today announced that its TearLab Osmolarity System has received a 2009 Medical Design Excellence Award (MDEA).

SAN DIEGO, April 6, 2009 -- OccuLogix, Inc., dba TearLab Corporation (Tearlab) (Nasdaq:TEAR) (TSX:TLB), announced that its financial statements for the year ended December 31, 2008, filed with its Annual Report on Form 10-K on March 31, 2009, included an audit report of Ernst & Young LLP, its Independent Registered Public Accounting Firm, dated March 25, 2009, which contained a going concern qualification.

SAN DIEGO, March 26, 2009 -- OccuLogix, Inc., dba TearLab Corporation (Tearlab) (Nasdaq:TEAR) (TSX:TLB) today reported its consolidated financial results for the quarter and the year ended December 31, 2008. All dollar amounts are expressed in U.S. currency, and results are reported in accordance with United States generally accepted accounting principles.

SAN DIEGO, March 16, 2009 -- OccuLogix, Inc. dba TearLab Corporation (Nasdaq:TEAR) (TSX:TLB) today announced that Benjamin Sullivan, PhD, Chief Scientific Officer for the Company, is scheduled to present at the Cowen & Company 29th Annual Health Care Conference in Boston, Massachusetts. A live webcast of its presentation scheduled for Tuesday, March 17, 2009, at 1:40 p.m. Eastern Time (10:40 a.m. Pacific Time), may be accessed via the Internet.

SAN DIEGO, March 11, 2009 -- OccuLogix, Inc. dba TearLab Corporation (Nasdaq:TEAR) (TSX:TLB) today announced that it has initiated an international clinical study which is designed to demonstrate the efficacy of the TearLab(tm) Osmolarity System as a practical tool for the diagnosis and assessment of severity of Dry Eye Disease (DED) by measuring the osmolarity of tears. Osmolarity, simply stated, is a measure of the concentration of particles or solute per liter of solution.

SAN DIEGO, Feb. 5, 2009 -- OccuLogix, Inc. dba TearLab Corporation (Nasdaq:TEAR)(TSX:TLB) has announced that it has changed its independent registered public accounting firm from Ernst & Young LLP (Canada) ("EY Canada") to Ernst & Young LLP (United States) ("EY United States") to act as its auditors, commensurate with moving its corporate headquarters from Canada to San Diego, California.

SAN DIEGO, Jan. 20, 2009 -- OccuLogix, Inc. dba TearLab Corporation (Nasdaq:TEAR) (TSX:TLB) today announced that Anthony E. Altig has been appointed to its Board of Directors and will also serve as the chairman of the Audit Committee of the Board.

SAN DIEGO, Jan. 16, 2009 -- OccuLogix, Inc. dba TearLab Corporation (Nasdaq:TEAR) (TSX:TLB) today announced that the Company will immediately begin conducting business as TearLab Corporation and has changed its stock ticker symbols on the NASDAQ and Toronto Stock Exchange to TEAR and TLB, respectively. The official name change will be effective once stockholder approval is received.